Mohs Surgery Denied by Insurance? How to Appeal

Mohs micrographic surgery is the gold-standard treatment for many non-melanoma skin cancers (NMSC), offering the highest cure rates and maximum tissue preservation. Despite its clinical superiority, insurance companies regularly deny Mohs surgery — either upfront through Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization or after the fact as a claim denial. Here's how to fight back using the Appropriate Use Criteria (AUC) and ACMS guidelines.

Why Insurers Deny Mohs Surgery

Wrong location: Insurers may argue that Mohs is unnecessary for skin cancers on the trunk or extremities, even when high-risk features are present.

Tumor type restrictions: Some payers limit Mohs coverage to basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), denying it for other cancers like dermatofibrosarcoma protuberans (DFSP) or lentigo maligna.

Size thresholds: Some policies include minimum size requirements that do not align with clinical evidence or Appropriate Use Criteria.

"Excision sufficient" argument: Insurers sometimes argue that standard excision with margins is adequate, ignoring cure rate differences and tissue-preservation benefits of Mohs — particularly important for cosmetically and functionally sensitive areas.

Reconstruction denial: After approving the Mohs procedure itself, insurers separately deny the reconstruction of the resulting defect.

The Appropriate Use Criteria (AUC): Your Key Documentation Tool

The American College of Mohs Surgery (ACMS) and American Academy of Dermatology developed Appropriate Use Criteria for Mohs surgery. The AUC evaluates appropriateness based on:

Tumor type: BCC, SCC, and selected other NMSC types meet AUC criteria.

Anatomic location:

• Area H (highest risk): Central face, eyelids, eyebrows, nose, lips, chin, ear, hands, feet, genitalia, nails — Mohs is appropriate for virtually any size here
• Area M (moderate risk): Cheeks, forehead, scalp, neck — Mohs appropriate for tumors 1cm or larger or with aggressive histology
• Area L (lower risk): Trunk and extremities — Mohs appropriate for tumors 2cm or larger or with aggressive features

Tumor characteristics: Aggressive histologic subtypes, recurrent tumors, poorly defined clinical margins, perineural or perivascular invasion all support Mohs appropriateness.

Patient factors: Immunosuppression, history of prior radiation therapy, or genetic conditions (xeroderma pigmentosum, basal cell nevus syndrome) support Mohs appropriateness.

Your appeal letter should explicitly map your case to AUC criteria by location, size, histology, and patient factors.

High-Risk Basal Cell Carcinoma: What to Document

For BCC specifically, high-risk features that strengthen a Mohs appropriateness argument include:

• Morpheaform, infiltrative, or basosquamous subtypes on pathology report
• Tumor location on nose, ears, eyelids, or scalp (Area H/M)
• Recurrent BCC at a previously treated site
• Ill-defined clinical margins on examination
• Tumor diameter 1cm or larger on the face or 2cm or larger on trunk/extremities
• Immunocompromised patient (organ transplant recipient, HIV, chronic immunosuppressive therapy)

Each of these features should be explicitly documented in the pathology report and the Mohs surgeon's clinical notes.

Recurrent vs. Primary Cancer Appeals

Recurrent skin cancer — cancer returning at a previously treated site — has a much stronger Mohs appropriateness argument than primary cancer. Document:

• Date and method of prior treatment
• Pathology confirming recurrence
• Extent of scar tissue that limits standard re-excision margins
• Mohs surgeon's clinical assessment of margin status

For primary cancer appeals, emphasize location (Area H), histologic subtype, size, and any individual patient risk factors.

Reconstruction After Mohs: A Separate Fight

Denial of reconstruction after Mohs is a separate but common problem. The reconstruction — whether a simple linear closure, complex flap, or graft — is an integral part of skin cancer treatment, not a cosmetic procedure. Your appeal should:

• Document the size of the surgical defect (in cm) left after tumor clearance
• Identify the reconstructive method selected and the clinical reason for that method (e.g., local flap chosen to preserve eyelid function)
• Cite CPT coding guidelines showing reconstruction codes are distinct from excision codes
• Argue that denying reconstruction leaves the patient with an open wound, which constitutes a medical emergency

ACMS Guidelines and Professional Standards

The American College of Mohs Surgery (mohssurgery.org) has published position statements, AUC documentation, and patient advocacy resources. Reference ACMS guidelines directly in your appeal. Note your surgeon's ACMS fellowship training if applicable — this attests to expertise and the appropriateness of the treatment recommendation.

Fight Back With ClaimBack

ClaimBack's skin cancer appeal tools guide you through mapping your case to AUC criteria, documenting high-risk BCC features, and framing reconstruction as medically necessary.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied